A Study to Identify the Risk of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients With Type 2 Diabetes in Clinical Practice and to Evaluate the Clinical Usefulness of Dapagliflozin/Pioglitazone Combination Therapy

NCT06649162 · clinicaltrials.gov ↗
RECRUITING
Status
10000
Enrollment
INDUSTRY
Sponsor class

Conditions

Sponsor

Boryung Pharmaceutical Co., Ltd